Снижение риска осложнений у больных артериальной гипертензией: преимущества комбинированной гипотензивной терапии периндоприлом и амлодипином (по материалам Конгресса Европейского общества артериальной гипертонии 2011 года)
https://doi.org/10.18705/1607-419X-2011-17-4-372-378
Аннотация
Эффективный контроль уровня артериального давления (АД) остается ключевым фактором снижения сердечно-сосудистой заболеваемости и смертности. Основными критериями выбора рациональной гипотензивной терапии являются: оптимальный гипотензивный эффект и доказанное снижение риска сердечно-сосудистых осложнений и смертности. 18 июня 2011 года в рамках Европейского Конгресса по артериальной гипертензии (АГ) и сердечно-сосудистой профилактике состоялся симпозиум «Смертельна ли АГ сегодня?», на котором рассматривались вопросы эффективной гипотензивной терапии у больных АГ с помощью фиксированной комбинации периндоприла и амлодипина (препарат престанс). Препарат может быть рекомендован больным с неконтролируемой АГ, с высоким риском развития осложнений, сахарным диабетом или ишемической болезнью сердца.
Об авторах
Ю. А. Карпов
ФГУ РК НПК Минздравсоцразвития РФ, Москва
Россия
Россия
А. Т. Шубина
ФГУ РК НПК Минздравсоцразвития РФ, Москва
Россия
Россия
Список литературы
1. Lawes C.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lawes%20CM%22%5BAuthor%5D>., Vander Hoorn S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Vander%20Hoorn%20S%22%5BAuthor%5D>., Rodgers A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rodgers%20A%22%5BAuthor%5D>; International Society of Hypertension <http://www.ncbi.nlm.nih.gov/pubmed?term=%22International%20Society%20of%20Hypertension%22%5BCorporate%20Author%5D>. Global burden of blood-pressure-related disease, 2001 // Lancet. <http://www.ncbi.nlm.nih.gov/pubmed?term=Lawes%2C%20Hoorn%20Lancet%202008%3B%20371%3A%201513-1518> - 2008. - Vol. 371, № 9623. - P. 1513-1518.
2.
3. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context // Lancet. - 1990. - Vol. 335, № 8693. - P. 827-838.
4.
5. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J <http://www.ncbi.nlm.nih.gov/pubmed?term=European%20Heart%20J%202007%3B%2028%2812%29%3A%201462-1526>. - 2007. - Vol. 28, № 12. - P. 1462-1536.
6.
7. Hansson L., Zanchetti J.A., Carruthers S.G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial // Lancet. - 1998. - Vol. 351, № 9118. - P. 1756 -1762.
8.
9. Bahl V.K <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bahl%20VK%22%5BAuthor%5D>., Jadhav U.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jadhav%20UM%22%5BAuthor%5D>., Thacker H.P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thacker%20HP%22%5BAuthor%5D>. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study // Am. J. Cardiovasc. Drugs <http://www.ncbi.nlm.nih.gov/pubmed/19463019>. - 2009. - Vol. 9, № 3. - P. 135-142.
10.
11. Dahlцf B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dahl%C3%B6f%20B%22%5BAuthor%5D>., Sever P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sever%20PS%22%5BAuthor%5D>., Poulter N.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Poulter%20NR%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. <http://www.ncbi.nlm.nih.gov/pubmed?term=Dahl%C3%B6f%20Lancet%202005%3B%20366%3A%20895-906> - 2005. - Vol. 366, № 9489. - P. 895-906.
12.
13. Rothwell P.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rothwell%20PM%22%5BAuthor%5D>., Howard S.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Howard%20SC%22%5BAuthor%5D>., Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet <http://www.ncbi.nlm.nih.gov/pubmed?term=Rothwell%20AND%20Lancet%202010%3B%20375%289718%29%3A%20895-905>. - 2010. - Vol. 375, № 9718. - P. 895-905.
14.
15. Rothwell P.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rothwell%20PM%22%5BAuthor%5D>., Howard S.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Howard%20SC%22%5BAuthor%5D>., Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>. et al.; ASCOT-BPLA and MRC Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT-BPLA%20and%20MRC%20Trial%20Investigators%22%5BCorporate%20Author%5D>. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke // Lancet Neurol <http://www.ncbi.nlm.nih.gov/pubmed?term=Rothwell%20AND%20Lancet%20Neurol%202010%3B%209%285%29%3A%20469-480>. - 2010. - Vol. 9, № 5. - P. 469-480.
16.
17. Perloff D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Perloff%20D%22%5BAuthor%5D>., Sokolow M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sokolow%20M%22%5BAuthor%5D>., Cowan R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cowan%20R%22%5BAuthor%5D>. The prognostic value of ambulatory blood pressures // J. Am. Med. Assoc. <http://www.ncbi.nlm.nih.gov/pubmed?term=Sokolow%20%20AND%20JAMA%201983> - 1983. - Vol. 249, № 20. - P. 2792-2798.
18.
19. Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>., Stanton A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stanton%20A%22%5BAuthor%5D>., Thijs L <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thijs%20L%22%5BAuthor%5D>. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study // Hypertension <http://www.ncbi.nlm.nih.gov/pubmed?term=Dolan%20AND%20Hypertension%202005%3B%2046%281%29%3A%20156-161>. - 2005. - Vol. 46, № 1. - P. 156-161.
20.
21. Dolan E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dolan%20E%22%5BAuthor%5D>., Stanton A.V <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Stanton%20AV%22%5BAuthor%5D>., Thom S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thom%20S%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-an Anglo-Scandinavian cardiac outcomes trial substudy // J. Hypertens. <http://www.ncbi.nlm.nih.gov/pubmed?term=Dolan%20AND%20Hypertension%202009%3B%2027%284%29> - 2009. - Vol. 27, № 4. - P. 876-885.
22.
23. Messerli F.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Messerli%20FH%22%5BAuthor%5D>., Mancia G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mancia%20G%22%5BAuthor%5D>., Conti C.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Conti%20CR%22%5BAuthor%5D>. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? // Ann. Intern. Med <http://www.ncbi.nlm.nih.gov/pubmed?term=Musserli%20AND%20Ann%20Intern%20Med%202006%3B%20144%2812%29%3A%20884-893>. - 2006. - Vol. 144, № 12. - P. 884-893.
24.
25. Williams B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Williams%20B%22%5BAuthor%5D>., Lacy P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lacy%20PS%22%5BAuthor%5D>., Thom S.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thom%20SM%22%5BAuthor%5D>. et al.; CAFE Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22CAFE%20Investigators%22%5BCorporate%20Author%5D>; Anglo-Scandinavian Cardiac Outcomes Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Anglo-Scandinavian%20Cardiac%20Outcomes%20Trial%20Investigators%22%5BCorporate%20Author%5D>; CAFE Steering Committee and Writing Committee <http://www.ncbi.nlm.nih.gov/pubmed?term=%22CAFE%20Steering%20Committee%20and%20Writing%20Committee%22%5BCorporate%20Author%5D>. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. <http://www.ncbi.nlm.nih.gov/pubmed?term=Circulation%202006%3B%20113%3A%201213-1225> - 2006. - Vol. 113, № 9. - P. 1213-1225.
26.
27. Poulter N.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Poulter%20NR%22%5BAuthor%5D>., Dobson J.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dobson%20JE%22%5BAuthor%5D>., Sever P.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sever%20PS%22%5BAuthor%5D>. et al.; ASCOT Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ASCOT%20Investigators%22%5BCorporate%20Author%5D>. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) // J. Am. Coll. Cardiol. <http://www.ncbi.nlm.nih.gov/pubmed?term=Poulter%20AND%20JACC%202009%3B%2054%2813%29%3A%201154-61> - 2009. - Vol. 54, № 13. - P. 1154-1561.
28.
29. Dahlof B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. - 2002. - Vol. 359, № 9311. - P. 995-1003.
30.
31. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial // Lancet. - 1999. - Vol. 353, № 9153. - P. 611-616.
32.
33. Messerli F.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Messerli%20FH%22%5BAuthor%5D>., Bangalore S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bangalore%20S%22%5BAuthor%5D>., Ruschitzka F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ruschitzka%20F%22%5BAuthor%5D>. Angiotensin receptor blockers: baseline therapy in hypertension? // Eur. Heart J. <http://www.ncbi.nlm.nih.gov/pubmed?term=Messerli%20F.H.%2C%20Bandalore%20S.%2C%20Ruschitzka%20F.%20Eur%20Heart%20J%202009%3B%2030%2820%29%3A%202427-2430> - 2009. - Vol. 30, № 20. - P. 2427-2430.
34.
35. Strauss M.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Strauss%20MH%22%5BAuthor%5D>., Hall A.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hall%20AS%22%5BAuthor%5D>. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. <http://www.ncbi.nlm.nih.gov/pubmed?term=Angiotensin%20Receptor%20Blockers%20May%20Increase%20Risk%20of%20Myocardial%20Infarction%20Unraveling%20the%20ARB-MI%20Paradox> - 2006. - Vol. 114, № 8. - P. 838-854.
36.
37. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.
38.
39. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke and transient ischemic attack // Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041.
40.
41. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. - 2003. - Vol. 362, № 9386. -P. 782-788.
42.
43. Bertrand M.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bertrand%20ME%22%5BAuthor%5D>., Ferrari R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrari%20R%22%5BAuthor%5D>., Remme W.J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Remme%20WJ%22%5BAuthor%5D>. et al.; EUROPA Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22EUROPA%20Investigators%22%5BCorporate%20Author%5D>. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study // Am. Heart J <http://www.ncbi.nlm.nih.gov/pubmed?term=Bertrand%20M.E.%20Am%20Heart%20J%202010%3B%20159%3A%20795-802>. - 2010. - Vol. 159, № 5. - P. 795-802.
44.
45. Ferrari R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrari%20R%22%5BAuthor%5D>. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril // Expert Rev. Cardiovasc. Ther <http://www.ncbi.nlm.nih.gov/pubmed/15723572>. - 2005. - Vol. 3, № 1. - P. 15-29.
46.
47. Jamerson K <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jamerson%20K%22%5BAuthor%5D>., Weber M.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Weber%20MA%22%5BAuthor%5D>., Bakris G.L <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bakris%20GL%22%5BAuthor%5D>. et al; ACCOMPLISH Trial Investigators <http://www.ncbi.nlm.nih.gov/pubmed?term=%22ACCOMPLISH%20Trial%20Investigators%22%5BCorporate%20Author%5D>. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. <http://www.ncbi.nlm.nih.gov/pubmed?term=N%20Engl%20J%20Med%202008%3B%20359%3A%202417-28> - 2008. - Vol. 359, № 23. - P. 2417-2428.
48.
Рецензия
Для цитирования:
Карпов Ю.А., Шубина А.Т. Снижение риска осложнений у больных артериальной гипертензией: преимущества комбинированной гипотензивной терапии периндоприлом и амлодипином (по материалам Конгресса Европейского общества артериальной гипертонии 2011 года). Артериальная гипертензия. 2011;17(4):372-378. https://doi.org/10.18705/1607-419X-2011-17-4-372-378
For citation:
Karpov Y.A., Shubina A.T. The decrease of complication rate in hypertensives: Benefits of combined antihypertensive treatment by Perindopril and Amlodipine (adapted from the materials from the Annual Scientific Meeting of the European Society of Hypertension [ESH], 2011). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(4):372-378. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-4-372-378
Просмотров:
708
Послать статью по эл. почте 